The effect of long-acting beta2-agonists on airway inflammation in asthmatic patients.

[1]  S. Wenzel,et al.  Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. , 1999, American journal of respiratory and critical care medicine.

[2]  P. Howarth,et al.  The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. , 1999, The European respiratory journal.

[3]  P. Paggiaro,et al.  Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects , 1999, Thorax.

[4]  P. Barnes,et al.  Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. , 1999, American journal of respiratory and critical care medicine.

[5]  P. Howarth,et al.  The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. , 1999, American journal of respiratory and critical care medicine.

[6]  P. Hiemstra,et al.  Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium. , 1998, The European respiratory journal.

[7]  M. Sears,et al.  Potential masking effects of salmeterol on airway inflammation in asthma. , 1998, American journal of respiratory and critical care medicine.

[8]  F. Hargreave,et al.  Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial. , 1998, Canadian respiratory journal.

[9]  B. Zweiman,et al.  Comparison of Inflammatory Events during Developing Immunoglobulin E-Mediated Late-Phase Reactions and Delayed-Hypersensitivity Reactions , 1998, Clinical Diagnostic Laboratory Immunology.

[10]  P. Peachell,et al.  Salmeterol inhibition of mediator release from human lung mast cells by β‐adrenoceptor‐dependent and independent mechanisms , 1998, British journal of pharmacology.

[11]  Bissonnette Ey,et al.  Anti-inflammatory effect of β2-agonists: Inhibition of TNF-α release from human mast cells , 1997 .

[12]  D. Yates,et al.  Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients. , 1997, The European respiratory journal.

[13]  S. Wenzel,et al.  The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. , 1997, Chest.

[14]  L. Boulet,et al.  INFLUENCE OF SALMETEROL ON CHRONIC AND ALLERGEN-INDUCED AIRWAY INFLAMMATION IN MILD ALLERGIC ASTHMA: A PILOT STUDY , 1997 .

[15]  F. Dallegri,et al.  Inhibitory effect of salmeterol on the respiratory burst of adherent human neutrophils , 1996, Clinical and experimental immunology.

[16]  R. Wilson,et al.  Anti‐inflammatory, membrane‐stabilizing interactions of salmeterol with human neutrophils in vitro , 1996, British journal of pharmacology.

[17]  C. Giuntini,et al.  Present state of the controversy about regular inhaled beta-agonists in asthma. , 1995, The European respiratory journal.

[18]  P. Howarth,et al.  Bronchial biopsy evidence for leukocyte infiltration and upregulation of leukocyte-endothelial cell adhesion molecules 6 hours after local allergen challenge of sensitized asthmatic airways. , 1994, The Journal of clinical investigation.

[19]  R. Dahl,et al.  The effect of salmeterol on the early‐ and late‐phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein X , 1993, Allergy.

[20]  R. Townley,et al.  The effect of formoterol on the late asthmatic phenomena in guinea pigs. , 1992, The Journal of allergy and clinical immunology.

[21]  M. Palmqvist,et al.  Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting beta 2-agonist. , 1992, The Journal of allergy and clinical immunology.

[22]  M. Johnson,et al.  Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea‐pig lung and skin , 1992, British journal of pharmacology.

[23]  M. Johnson,et al.  Salmeterol: a potent and long‐acting inhibitor of inflammatory mediator release from human lung , 1991, British journal of pharmacology.

[24]  R. Ballard,et al.  Airways inflammation in nocturnal asthma. , 1991, The American review of respiratory disease.

[25]  S. Holgate,et al.  Protection against allergen-induced asthma by salmeterol , 1990, The Lancet.